Clinical Trials Logo
  1. Home
  2. Metastatic Sarcoma
  3. NCT01112384

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas — IND200  

Metastatic Sarcoma Clinical Trial

Official title:
A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Clinical Trial Summary

The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma. This research is being done because there is a need for better treatment options for advanced or recurring sarcoma. SB939 has been shown to shrink tumours in animals and some people and seems promising but it is not clear if it has any positive effects in sarcoma.

Clinical Trial Description

Objectives: 1. - To determine the efficacy of SB939 in translocation associated sarcoma patients. 2. - To determine response duration, stable disease rate and progression free survival. 3. - To evaluate toxicity of SB939. 4. - To investigate potential molecular factors predictive of response. 60mg SB939 will be given every other day 3 times a week for 3 weeks followed by a week off. Patients may receive a maximum of 12 cycles if they have a response to treatment in the absence of disease progression or unacceptable toxicity. Patients with stable disease may continue therapy for a maximum of 6 cycles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01112384
Study type Interventional
Source Canadian Cancer Trials Group
Contact
Status Completed
Phase Phase 2
Start date October 21, 2010
Completion date January 16, 2014
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Completed NCT01106872 - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase 1
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3
Completed NCT03357315 - Mix Vaccine for Metastatic Sarcoma Patients Phase 1/Phase 2
Active, not recruiting NCT05448820 - YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma Phase 1/Phase 2
Active, not recruiting NCT04595747 - Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Not yet recruiting NCT06298916 - 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer Phase 1/Phase 2
Recruiting NCT04693377 - Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial N/A
Recruiting NCT03168061 - Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma Phase 1/Phase 2
Not yet recruiting NCT05835154 - A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma N/A
Not yet recruiting NCT04199026 - Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Early Phase 1
Not yet recruiting NCT06235125 - Safety and Feasibility of Intraoperative Visualization With Cytalux in Children Phase 1
Recruiting NCT04771520 - Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Phase 2
Recruiting NCT05711615 - Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Phase 1
Completed NCT03823144 - Intravital Microscopy in Human Solid Tumors N/A
Recruiting NCT04430725 - Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
Completed NCT02192346 - α-TEA in Advanced Cancer Phase 1
Completed NCT02448537 - A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas Phase 2
Terminated NCT02609984 - Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) Phase 2